5N-Bicalutamide
Clinical data | |
---|---|
Other names | 5-Azabicalutamide |
Drug class | Nonsteroidal antiandrogen |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C17H13F4N3O4S |
Molar mass | 431.36 g·mol−1 |
3D model (JSmol) | |
| |
|
5N-Bicalutamide, or 5-azabicalutamide, is a highly potent nonsteroidal antiandrogen (NSAA) which was discovered in 2016.[1][2] It is a structural modification of bicalutamide differing it from it only by the replacement of a carbon atom with a nitrogen atom in one of its phenyl rings.[1] Similarly to bicalutamide, the drug acts as a selective antagonist of the androgen receptor (AR).[1] However, unlike bicalutamide, it is a reversible covalent antagonist and stays bound to the receptor for a far longer amount of time.[1] As a result of this difference, 5N-bicalutamide has markedly improved potency relative to bicalutamide, with approximately 150-fold higher affinity for the AR (Ki = 0.15 nM versus 22.3 nM) and about 20-fold greater functional inhibition (IC50 = 15 nM versus 310 nM) of the AR.[1] Future studies of 5N-bicalutamide in normal and mutated prostate cancer cells are planned or underway and it is anticipated that N-bicalutamide may be able to overcome resistance.[1] to current antiandrogens that are used in the treatment of prostate cancer.[1]
Enzalutamide and related second-generation NSAAs like RD-162 and apalutamide were derived from bicalutamide and as a result are similar to it in chemical structure.[1] They have up to about 10-fold higher affinity for the AR than does bicalutamide and hence are comparatively more potent and efficacious antiandrogens.[1] However, their structures are rigidified such that the analogous structural modification that was done with bicalutamide to create 5N-bicalutamide could not be used to increase affinity or potency with them.[1] Enzalutamide was described in 2013 as "the emperor of all antiandrogens" and other second-generation NSAAs have similar potency to it,[3] so 5N-bicalutamide would appear to be among the most potent AR antagonists to have been developed thus far.[1]
See also
References
- ^ a b c d e f g h i j k de Jesus Cortez F, Nguyen P, Truillet C, Tian B, Kuchenbecker KM, Evans MJ, et al. (December 2017). "Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen". ACS Chemical Biology. 12 (12): 2934–2939. doi:10.1021/acschembio.7b00702. PMID 28981251. S2CID 24974359.
- ^ US Patent 10053433B2, England, Pamela M.; Fletterick, R. J. & Kuchenbecker, K. et al., published 2016
- ^ Antonarakis ES (June 2013). "Enzalutamide: The emperor of all anti-androgens". Translational Andrology and Urology. 2 (2): 119–120. doi:10.3978/j.issn.2223-4683.2012.09.04. PMC 3785324. PMID 24076589.
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Infobox drug articles with non-default infobox title
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Aromatic nitriles
- Benzosulfones
- Experimental cancer drugs
- Hormonal antineoplastic drugs
- Nonsteroidal antiandrogens
- Pyridines
- Tertiary alcohols
- Trifluoromethyl compounds
- All stub articles
- Antineoplastic and immunomodulating drug stubs
- Genito-urinary system drug stubs